Urologia Internationalis
Original Paper
Intravesical Heparin and Peripheral Neuromodulation on Interstitial CystitisBaykal K. · Şenkul T. · Sen B. · Karademir K. · Adayener C. · Erden D.GATA Haydarpaşa Training Hospital, Department of Urology, Uskudar/Istanbul, Turkey
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: June 02, 2004
Accepted: December 16, 2004
Published online: May 18, 2005
Issue release date: May 2005
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 1
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Abstract
Introduction: We wanted to evaluate the therapeutic effect of intravesical heparin and peripheral neuromodulation on patients with interstitial cystitis. Materials and Methods: From March 2002 to August 2003, 8 female and 2 male subjects conform to the NIDDK criteria and not responsive to the previous conventional treatments were included in the study. Wisconsin pain scores, maximal cystometric capacities, and night and day voiding frequencies were determined and these studies were repeated in the 2nd and 12th months of the treatment with 10,000 units intravesical heparin and peripheral neuromodulation. Frequency of the treatment was once a week during first 8 weeks, once in 2 weeks in the following 8 weeks, and once in 3 weeks four times. Then, it was decreased to once a month. Results: The mean follow-up period was 13 months (12–16 months). Day and night voiding frequency were significantly better in the 2nd and 12th months, when compared to pretreatment values. The Wisconsin pain scores were 62.5 ± 13.9% and 62.8 ± 15.2% in the 2nd and the 12th months, respectively. The average increase in the maximum cystometric capacity was 54.8 ± 27.4% and 52.5 ± 31.6% in the 2nd and the 12th months, respectively. Conclusions: Intravesical heparin and peripheral neuromodulation combination seems to be an alternative for patients with interstitial cystitis not responsive to other treatments.
© 2005 S. Karger AG, Basel
Related Articles:
References
- Fall M, Johansson SL, Vahlne A: A clinicopathological and virological study of interstitial cystitis. J Urol 1985;133:771–773.
- Peeker R, Enerback L, Fall M, Aldenborg F: Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. J Urol 2000;163:1009–1015.
- Parsons CL, Lilly JD, Stein P: Epithelial dysfunction in nonbacterial cystitis. J Urol 1991;145:732–735.
- Harrington DS, Fall M, Johansson SL: Interstitial cystitis: bladder mucosa lymphocyte immunophenotyping and peripheral blood flow cytometry analysis. J Urol 1990;144:868–871.
- Ehren I, Hosseini A, Lundberg JO, Wiklund NP: Nitric oxide: a useful gas in the detection of lower urinary tract inflammation. J Urol 1999;162:327–329.
-
Parsons CL: Interstisyel cystitis; in Ostergard DR, Bent AE (eds): Urogynaecology and Urodynamics, ed 4. Baltimore, Williams & Wilkins. 1996, pp 409–427.
- Elbadawi A: Interstitial cystitis: A critique of current concepts with new proposal for pathologic diagnosis and pathogenesis. Urology 1997;49(5A suppl):14–40.
- Peters KM, Carey JM, Konstandt DB: Sacral neuromodulation for the treatment of refractory interstitial cystitis: Outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct 2003;14:223–228.
- Comiter CV: Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: A prospective study. J Urol 2003;169:1369–1373.
- Maher CF, Carey MP, Dwyer PL, Schluter PL: Percutaneous sacral nerve root neuromodulation for intractable interstitial cystitis. J Urol 2001;165:884–886.
- Govier FE, Litwiller S, Nitti V, Kreder KJ Jr, Rosenblatt P: Percutaneous afferent neuromodulation for the refractory overactive bladder: Results of a multicenter study. J Urol 2001;165:1193–1198.
-
Parsons CL: Interstitial cystitis; in Weiss RM, George N, O’Reilly PH (eds): Comprehensive Urology. London, Mosby, 2001, pp 493–507.
- Perez-Marrero R, Emerson LE, Feltis JT: A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 1988;140:36–39.
- Theoharides TC, Sart GR: Hydroxyzine therapy for interstitial cystitis. Urology 1997;49:108–110.
- Messing EM, Stamey TA: Interstitial cystitis: early diagnosis, pathology, and treatment. Urology 1978;12:381–392.
- Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR: Pentosan polysulfate sodium for therapy of interstitial cystitis: A double-blind placebo-controlled clinical study. Urology 1990;35:552–558.
- Hanno PM: Analysis of long-term Elmiron therapy for interstitial cystitis. Urology 1997;49:93–99.
-
Hand JR: Interstitial cystitis: Report of 223 cases. J Urol 1949;61:291–293.
External Resources
- Galloway NT, Gabale DR, Irwin PP: Interstitial cystitis or reflex sympathetic dystrophy of the bladder? Semin Urol 1991;9:148–153.
- Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB: Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency and retention. Urology 2000;56(6 suppl 1):87–91.
- Shaker HS, Hassouna M: Sacral nerve root neuromodulation: An effective treatment for refractory urge incontinence. J Urol 1998;159:1516–1519.
- Klingler HC, Pycha A, Schmidbauer J, Marberger M: Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: A urodynamic-based study. Urology 2000;56:766–771.
- van Balken MR, Vandoninck V, Gisolf KW, Vergunst H, Kiemeney LA, Debruyne FM: Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol 2001;166:914–918.
- Sun Y, Chai TC: Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. BJU Int 2002;90:381–385.
-
Rovner E, Propert KJ, Brensinger C, Wein AJ, Foy M, Kirkemo A: Treatments used in women with interstitial cystitis: The interstitial cystitis database (ICDB) study experience. The Interstitial Cystitis Data Base Study Group. Urology 2000;56:940–945.
External Resources
- Parsons CL, Housley T, Schmidt JD, Lebow D: Treatment of interstitial cystitis with intravesical heparin. Br J Urol 1994;73:504–507.
Article / Publication Details
Received: June 02, 2004
Accepted: December 16, 2004
Published online: May 18, 2005
Issue release date: May 2005
Number of Print Pages: 4
Number of Figures: 1
Number of Tables: 1
ISSN: 0042-1138 (Print)
eISSN: 1423-0399 (Online)
For additional information: https://www.karger.com/UIN
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
